Troy Wichterman Sells 987 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 987 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares in the company, valued at approximately $3,290,468.58. This trade represents a 0.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, November 26th, Troy Wichterman sold 581 shares of BioLife Solutions stock. The shares were sold at an average price of $27.20, for a total transaction of $15,803.20.
• On Tuesday, November 12th, Troy Wichterman sold 147 shares of BioLife Solutions stock. The stock was sold at an average price of $26.19, for a total transaction of $3,849.93.
• On Wednesday, October 30th, Troy Wichterman sold 894 shares of BioLife Solutions stock. The shares were sold at an average price of $23.15, for a total transaction of $20,696.10.

BioLife Solutions Stock Up 2.1 %

Shares of NASDAQ BLFS opened at $27.69 on Friday. The stock has a market capitalization of $1.28 billion, a P/E ratio of -26.12 and a beta of 1.92. The stock’s fifty day moving average is $25.99 and its 200 day moving average is $24.29. BioLife Solutions, Inc. has a 52 week low of $14.50 and a 52 week high of $28.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

Analysts Set New Price Targets

BLFS has been the topic of several research reports. TD Cowen upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright reduced their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. KeyCorp increased their price objective on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Craig Hallum boosted their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, Benchmark reiterated a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and an average target price of $29.43.

Hedge Funds Weigh In On BioLife Solutions

Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in shares of BioLife Solutions by 3.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 275,570 shares of the medical equipment provider’s stock worth $5,905,000 after acquiring an additional 8,216 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of BioLife Solutions by 4.7% in the 2nd quarter. Rhumbline Advisers now owns 87,473 shares of the medical equipment provider’s stock valued at $1,875,000 after purchasing an additional 3,912 shares in the last quarter. Arizona State Retirement System bought a new position in shares of BioLife Solutions in the 2nd quarter valued at $217,000. Los Angeles Capital Management LLC acquired a new position in shares of BioLife Solutions during the 2nd quarter worth $430,000. Finally, Texas Permanent School Fund Corp lifted its position in shares of BioLife Solutions by 8.7% during the 2nd quarter. Texas Permanent School Fund Corp now owns 33,859 shares of the medical equipment provider’s stock worth $726,000 after buying an additional 2,714 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.